Cellebrite DI (NASDAQ:CLBT) CEO Thomas Hogan Sells 139,713 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 139,713 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total value of $2,150,183.07. Following the sale, the chief executive officer owned 790,548 shares of the company’s stock, valued at approximately $12,166,533.72. The trade was a 15.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Cellebrite DI Stock Down 29.2%

Cellebrite DI stock opened at $10.80 on Friday. The business’s 50-day simple moving average is $14.52 and its 200 day simple moving average is $14.05. The stock has a market cap of $2.69 billion, a price-to-earnings ratio of 38.57, a P/E/G ratio of 1.89 and a beta of 1.18. Cellebrite DI Ltd. has a 12-month low of $9.58 and a 12-month high of $19.98.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.06. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%.The firm had revenue of $131.14 million during the quarter, compared to analysts’ expectations of $131.87 million. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.41 EPS for the current year.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors have recently modified their holdings of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its stake in Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after purchasing an additional 850 shares in the last quarter. Advisory Services Network LLC bought a new position in Cellebrite DI in the third quarter valued at approximately $40,000. CWM LLC boosted its holdings in shares of Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the period. First Horizon Corp increased its position in shares of Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after acquiring an additional 2,337 shares in the last quarter. Finally, Elevation Wealth Partners LLC acquired a new position in Cellebrite DI in the 2nd quarter worth $44,000. Institutional investors own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CLBT. Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC dropped their price objective on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, DA Davidson increased their target price on Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and an average price target of $21.80.

More Cellebrite DI News

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported second-quarter adjusted EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat, while subscription revenue continued to rise. Management also raised its adjusted EBITDA target. Cellebrite second-quarter earnings report
• Positive Sentiment: D.A. Davidson maintained its Buy rating, and one analyst argued that the selloff may be excessive relative to Cellebrite’s longer-term growth opportunity. D.A. Davidson rating
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, substantially above average volume, suggesting some traders were positioning for a rebound, although this is speculative rather than a fundamental catalyst.
• Neutral Sentiment: Cellebrite announced a planned CEO succession, with Shiven Ramji replacing Thomas E. Hogan effective August 13. The transition could bring a new strategic direction, but investors may initially view leadership change as an uncertainty. Cellebrite CEO succession announcement
• Negative Sentiment: The main pressure came from lowered guidance: third-quarter revenue was projected at $145 million-$148 million versus a $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million fell short of the $568.1 million estimate. The company also lowered its full-year ARR outlook, indicating weaker near-term growth than previously expected. Cellebrite 2026 outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate, and another earnings estimate placed EPS at $0.11 versus $0.12 expected. The combination of an ARR miss and weaker outlook outweighed the reported EPS beat. Cellebrite investigation notice
• Negative Sentiment: Several law firms announced investigations into possible securities-law violations and the accuracy of Cellebrite’s prior projections and disclosures. These are allegations, not findings, but they add legal and reputational risk after the selloff. Kaplan Fox investigation notice
• Negative Sentiment: CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, a 15% reduction in his position. Although the sale may be related to the leadership transition or personal financial planning, its timing can weigh on sentiment. SEC insider trading filing

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.